Thrive & Co.

Thrive & Co. offers an extensive peptide therapy program with 8 different peptides available, including metabolic peptides including Semaglutide, Tirzepatide, growth hormone secretagogues like CJC-1295, and other specialized compounds. Treatment selection is individualized based on comprehensive health assessments and patient goals.

The clinic's hormone optimization programs address testosterone deficiency, thyroid dysfunction, and estrogen imbalance through laboratory-guided protocols that incorporate peptide adjuncts such as Tesamorelin for visceral fat reduction in patients with metabolic syndrome or lipodystrophy patterns. PT-141 is available for patients experiencing sexual dysfunction unresponsive to conventional treatments, offering a melanocortin receptor-based alternative to phosphodiesterase inhibitors. NAD+ therapy is administered via IV infusion or subcutaneous injection to support cellular energy production, DNA repair mechanisms, and neurological function in patients managing chronic fatigue, cognitive decline, or recovery from substance dependence. Each peptide protocol at Thrive & Co. begins with comprehensive lab work including hormone panels, metabolic markers, and inflammatory indicators to establish baseline values and identify contraindications before treatment initiation.

Thrive & Co.'s medical team develops individualized treatment plans based on patient-specific health histories, current symptoms, and objective laboratory findings rather than applying standardized protocols across patient populations. Providers conduct detailed intake assessments that examine sleep architecture, stress response patterns, exercise capacity, dietary habits, and medication histories to identify root causes of hormonal imbalance or metabolic dysfunction. The clinic's approach to peptide therapy emphasizes proper dosing schedules, injection technique education, and monitoring for both therapeutic response and potential adverse effects through scheduled follow-up appointments that track symptom resolution and repeat laboratory values at clinically appropriate intervals.

Patients beginning treatment at Thrive & Co. receive detailed written protocols specifying peptide reconstitution procedures, storage requirements, injection site rotation schedules, and expected timelines for clinical response based on the specific peptides prescribed. The clinic provides ongoing access to medical staff for questions about injection technique, side effect management, or dosage adjustments as treatment progresses. For weight management patients using Semaglutide or Tirzepatide, the clinic implements gradual dose escalation protocols to minimize gastrointestinal side effects while achieving therapeutic GLP-1 receptor activation, with nutritional guidance addressing protein intake requirements and strategies to preserve lean muscle mass during caloric restriction. Hormone optimization patients receive education about the interplay between peptide therapy and endogenous hormone production, including potential impacts on hypothalamic-pituitary-gonadal axis function and the importance of monitoring for suppression or dysregulation.

Thrive & Co. serves patients throughout South Dakota via HIPAA-compliant telehealth platforms that enable remote consultations, treatment monitoring, and prescription management for established patients who cannot easily access the Sioux Falls location. The clinic's telehealth services include video consultations for initial assessments and follow-up appointments, electronic laboratory order placement with local draw station coordination, and home delivery of prescribed peptides and supplies through licensed compounding pharmacies. This hybrid care model allows the clinic to extend regenerative medicine access to patients in rural South Dakota communities while maintaining the clinical oversight necessary for safe peptide therapy administration. Thrive & Co. accepts new patients seeking alternatives to conventional hormone replacement, metabolic interventions, or aesthetic treatments, with initial consultations focused on determining candidacy for peptide-based protocols and establishing realistic expectations for treatment outcomes based on current evidence and individual patient factors.